- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04879043
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
July 13, 2023 updated by: Heidelberg Pharma AG
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients With Plasma Cell Disorders Including Multiple Myeloma
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The study will consists of two parts: a Part 1 dose escalation phase and a Part 2a expansion phase for safety, tolerability, PK, PD, and clinical activity testing.
The study will enroll subjects with relapsed/refractory MM or other plasma cell disorders expressing BCMA.
An adaptive 2-parameter Bayesian logistic regression model (BLRM) for dose-escalation with overdose control will be used in the dose-escalation phase for determination of the MTD or the RP2D.
Dose-expansion phase of the study aims to collect preliminary evidence of antitumor activity and to confirm the safety of the HDP-101 as a monotherapy.
Study Type
Interventional
Enrollment (Estimated)
78
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: András Strassz, MD
- Phone Number: + 49 6203 1009 0
- Email: clinical@hdpharma.com
Study Locations
-
-
-
Berlin, Germany, 12203
- Not yet recruiting
- Charité - Campus Benjamin Franklin Med. Klinik m.S. Hämatologie, Onkologie
-
Chemnitz, Germany, 09116
- Not yet recruiting
- Klinikum Chemnitz gGmbH, Klinik f. Innere Medizin III
-
Hamburg, Germany, 22763
- Not yet recruiting
- Asklepios Klinik Altona, Haematologie und internistische Onkologie
-
Heidelberg, Germany, 69120
- Recruiting
- Universitätsklinikum Heidelberg
-
Kiel, Germany, 24105
- Recruiting
- Universitätsklinikum Schleswig-Holstein
-
Köln, Germany, 50937
- Not yet recruiting
- Universitätsklinikum Köln
-
Lübeck, Germany, 23538
- Not yet recruiting
- UKSH Campus Lübeck Klinik für Hämatologie und Onkologie
-
Mainz, Germany, 55131
- Recruiting
- Universitätsklinikum Mainz
-
-
-
-
-
Budapest, Hungary, 1083
- Not yet recruiting
- Semmelweis University, Belgyogyaszati es Onkologiai Klinika
-
Budapest, Hungary, 1122
- Recruiting
- National Institute of Oncology, Department of Oncological Internal Medicine
-
-
-
-
-
Katowice, Poland, 40-519
- Recruiting
- Pratia Onkologia Katowice
-
Opole, Poland, 45-061
- Not yet recruiting
- Szpital Wojewódzki w Opolu
-
Łódź, Poland, 93-513
- Not yet recruiting
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi
-
-
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Winship Cancer Institute of Emory University
-
-
New York
-
New York, New York, United States, 10029
- Recruiting
- Mount Sinai, The Tisch Cancer Instutute
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female aged ≥18 years.
- Life expectancy >12 weeks.
- Eastern Cooperative Oncology Group Performance Status (PS) of 0 to 2.
- A confirmed diagnosis of active MM according to the diagnostic criteria established by the International Myeloma Working Group (IMWG).
- Must have undergone SCT or is considered transplant ineligible.
- Must have undergone prior treatments with antimyeloma therapy which must have included an immunomodulatory drug, proteasome inhibitor, and anti-CD38 treatment, alone or in combination. In addition, the patient should either refractory or intolerant to any established standard of care therapy providing a meaningful clinical benefit for the patient assessed by the Investigator.
- Measurable disease as per IMWG criteria.
- Adequate organ system function as defined in protocol.
Exclusion Criteria:
- For patient entering the Phase 2a part only: Prior treatment with any approved or experimental BCMA-targeting modalities are not allowed.
- Known central nervous system involvement.
- Plasma cell leukemia.
- History of congestive heart failure.
- Autologous or allogenic SCT within 12 weeks before the first infusion or is planning for autologous SCT.
- Symptomatic graft versus host disease post allogenic hemopoietic cell transplant within 12 months prior to the first study treatment infusion.
- Radiotherapy within 21 days prior to the first study treatment infusion.
- History of any other malignancy known to be active.
- Known human immunodeficiency virus infection.
- Patients with active infection requiring systemic anti-infective.
- Patients with positive test results for hepatitis B surface antigen or Hepatitis B core antigen.
- Patients with positive test results for hepatitis C virus (HCV) infection.
- Current active liver or biliary disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HDP-101
Participants will receive HDP-101 intravenously at one dose every 3 weeks (21 day cycle) until disease progression, intolerable toxicity, Investigator's discretion or patient withdrawal. During the phase 1 tolerability of different dose levels will be evaluated. During the phase 2a dose expansion part the recommended phase 2 dose (RP2D) of HDP-101 will be administered. |
HDP-101 is available as lyophilized white powder for preparation of infusion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients who experience dose-limiting toxicity (DLT) during the first cycle of treatment - Part 1 as defined in Clinical Study Protocol
Time Frame: Up to Day 21 (from first dose)
|
Up to Day 21 (from first dose)
|
|
Objective response rate (ORR)
Time Frame: Through study completion, an average of 1 year
|
Proportion of enrolled subjects who achieve a partial response (PR) or better, i.e. stringent complete response (sCR), complete response (CR), very good partial response (VGPR) and PR, according to the IMWG criteria.
|
Through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the safety and tolerability of HDP-101
Time Frame: Through study completion, an average of 1 year
|
Number of patients with serious and non-serious adverse events grouped by system organ class and preferred terms based on Common Terminology Criteria for Adverse Events (CTCAE v 5.0) classification.
|
Through study completion, an average of 1 year
|
To assess the anticancer activity of HDP-101 in terms of time-to-event (TTE)
Time Frame: Through study completion, an average of 1 year
|
Clinical efficacy of HDP-101 measured by Progression Free Survival (PFS) and Overall Survival (OS).
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Strassz A, Raab MS, Orlowski RZ, Kulke M, Schiedner G, Pahl A. A First in Human Study Planned to Evaluate HDP-101, an Anti-BCMA Amanitin Antibody-Drug Conjugate with a New Payload and a New Mode of Action, in Multiple Myeloma. Blood 2020; 136 (Supplement 1): 34. doi: https://doi.org/10.1182/blood-2020-142285
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 7, 2022
Primary Completion (Estimated)
August 1, 2024
Study Completion (Estimated)
May 1, 2025
Study Registration Dates
First Submitted
April 23, 2021
First Submitted That Met QC Criteria
May 4, 2021
First Posted (Actual)
May 10, 2021
Study Record Updates
Last Update Posted (Actual)
July 14, 2023
Last Update Submitted That Met QC Criteria
July 13, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Paraproteinemias
Other Study ID Numbers
- HDP-101-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on HDP-101
-
CHU de ReimsRecruiting
-
Mathew S. MaurerNational Heart, Lung, and Blood Institute (NHLBI); Yale University; Boston Medical... and other collaboratorsRecruitingAmyloid Cardiomyopathy, Transthyretin-RelatedUnited States
-
Universidad de AntioquiaRecruitingHypertensive Disorders of PregnancyColombia
-
TR TherapeuticsCompleted
-
Brigham and Women's HospitalRecruiting
-
Alaunos TherapeuticsCompleted
-
Abalonex, LLCNot yet recruitingTraumatic Brain Injury | Cerebral Edema
-
Benjamin IzarTerminatedLeiomyosarcoma | LiposarcomaUnited States
-
Flame BiosciencesCompletedHealthy SubjectsUnited States
-
Alaunos TherapeuticsCompleted